September 18th 2023
Kjersten Dosumu, DNP, MS, AGPCNP-BC, explains why investigators are optimistic about treating uterine leiomyosarcoma with olaparib and temozolomide.
2nd Annual International Congress on Pediatric Oncology
View More
Community Practice Connections™: 23rd Annual International Lung Cancer Congress®
View More
PER's Breast Cancer Symposia in San Antonio
Register Now!
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
Register Now!
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Register Now!
BURST CME™: Understanding Transfusion Dependence in Lower-Risk MDS
View More
BURST CME™: What Is the Real Risk in Lower-Risk MDS?
View More
BURST CME™: How Does Transfusion Burden Impact Real-World Outcomes in MDS?
View More
The Latest on Acute Lymphocytic Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
A Focus on Acute Myeloid Leukemia
View More
Medical Crossfire®: Onco-Nursing Best Practices for Managing AEs Related to CAR T-Cell Therapy from Treatment Center to Community
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Medical Crossfire®: Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
25th Annual International Lung Cancer Congress®
Register Now!
Community Practice Connections™: Multidisciplinary Strategies for Improving Outcomes in CML from Frontline Care… and Beyond!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
7th Annual School of Nursing Oncology™
View More
Crucial Conversations in R/R Multiple Myeloma: Nursing Strategies to Optimize Patient Communication and Improve Outcomes
View More
GlobaOncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of B-Cell Lymphomas with BTK Inhibitors
View More
Myeloma Management Considerations: Applying the Evidence With Monoclonal Antibody Based Regimens
View More
Establishing Medical Fitness is the First Step in Treating Patients with Advanced Ovarian Cancer
August 26th 2019Before considering intraperitoneal chemotherapy, or dose-dense chemotherapy, for newly diagnosed patients with advanced ovarian cancer, it's not vital to first determine whether the patient is medically fit for these treatments.
The Treatment Landscape for Recurrent Ovarian Cancer Is Evolving
August 25th 2019Chemotherapy is the foundation of treatment for patients with recurrent ovarian cancer, but according to Madeleine B. Courtney Brooks, MD, MPH, conversations regarding the potential for secondary debulking and use of bevacizumab (Avastin) may also be warranted.
FDA Approves Bevacizumab Biosimilar for 5 Cancer Types
June 28th 2019The Food and Drug Administration approved bevacizumab-bvzr (Zirabev) – a biosimilar for bevacizumab (Avastin) for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.
FDA Approves Olaparib for First-Line Maintenance in Gynecological Cancer
December 20th 2018The FDA has approved olaparib (Lynparza) as a maintenance treatment for patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy, as approved by an FDA-approved companion diagnostic assay.
FDA Grants Olaparib Priority Review for Frontline Maintenance in Ovarian Cancer
November 12th 2018The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for olaparib (Lynparza) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.
Olaparib Significantly Improves PFS in Advanced BRCA+ Ovarian Cancer
November 6th 2018The PARP inhibitor olaparib (Lynparza) significantly improved progression-free survival (PFS) as frontline maintenance therapy in women with BRCA-positive advanced ovarian cancer, according to findings reported at the 2018 European Society of Medical Oncology Congress.